Patient leaflets and SmPCs, drug interaction checker, official dosages and NHS pharmacy opening hours — all in one place.
Patient leaflets and SmPCs, drug interaction checker, official dosages and NHS pharmacy opening hours — all in one place.
The electronic medicines compendium (emc) no longer publishes a Summary of Product Characteristics for this product, which usually means it is no longer marketed in the UK. The patient leaflet below is kept for reference, but the product may not be available.
If you were prescribed this medicine, other products containing Glucose monohydrate, Sodium chloride may still be available. Do not stop your treatment — ask your pharmacist or GP what to use instead.
Sodium Chloride 0.18 & Glucose 4 Infusion 3. How you will be given Sodium Chloride 0.18 & Glucose 4 Infusion 4. Possible side effects 5. How to store Sodium Chloride 0.18 & Glucose 4 Infusion 6. Contents of the pack and other information
1. What Sodium Chloride 0.18 & Glucose 4 Infusion is and what it is used for Sodium Chloride 0.18 & Glucose 4 Infusion is a solution of the following substances in water:
TH-30-02-199
1
– – – –
you are in pain you have had surgery you have infections, burns o brain disease you have diseases linked to your heart, liver, kidneys or central nervous system
Warnings and precautions Please tell your doctor if you have or have had any of the following medical conditions.
When you are given this infusion, your doctor will take blood and urine samples to monitor:
2
Some medicines act on the hormone vasopressin. These may include:
•
if you have had head injury within the past 24 hours Your doctor will take into account if you are receiving parenteral nutrition (nutrition given by infusion into a vein). During long-term treatment with Sodium Chloride 0.18 & Glucose 4 Infusion, you may need to be given extra nutrition. Your doctor should also monitor the level of potassium in your blood to avoid this becoming lower than normal (hypokalaemia).
Children Special care should be taken when giving this solution to children, infants, and newborns (especially premature babies and those with low birth weight). Children, infants and newborns may not have a good ability to handle the chemicals in the solution. Younger children are at an increased risk of developing levels of sugar in the blood that are either too high or too low, and therefore need close monitoring during treatment to ensure that sugar levels are controlled. Low sugar levels newborns can cause prolonged seizures, coma and brain damage. High sugar levels have been associated with bleeding into the brain, bacterial and fungal infection, damage to the eye (retinopathy of prematurity), infections in the intestinal tract, lung problems, prolonged length of hospital stay and death.
Other medicines that can affect or be affected by Sodium Chloride 0.18 & Glucose 4 Infusion:
Sodium Chloride 0.18 & Glucose 4 Infusion with food, drink and alcohol
Children are at higher risk for having or developing a too low sodium concentration in their blood (hyponatraemia). Hyponatraemia can lead to headache, nausea, seizures, lethargy, coma, swelling of the brain (cerebral oedema) and death. Acute hyponatraemic encephalopathy is a serious complication, especially in children.
You should ask your doctor about what you can eat or drink.
Pregnancy, breast-feeding and fertility If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or nurse for advice before taking this medicine. Sodium Chloride 0.18 & Glucose 4 Infusion can be used during breastfeeding. If another medicine is to be added to your solution for infusion during pregnancy or breast-feeding you should:
Your doctor knows this and will closely monitor the amount of chemicals such as glucose (sugar), sodium and chloride in your child's blood (plasma electrolytes)
Other medicines and Sodium Chloride 0.18 & Glucose 4 Infusion Tell your doctor or nurse if you are taking or have recently taken any other medicines. It is particularly important that you inform your doctor if you are taking:
Driving and using machines Sodium Chloride 0.18 & Glucose 4 Infusion does not affect your ability to drive or use machines.
TH-30-02-199
3
Sodium Chloride 0.18 & Glucose 4 Infusion You will be given Sodium Chloride 0.18 & Glucose 4 Infusion by a doctor or nurse. Your doctor will decide on how much you need and when it is to be given. This will depend on your age, weight, condition and the reason for treatment. The amount you are given may also be affected by other treatments you are receiving. You should NOT be given Sodium Chloride 0.18 & Glucose 4 Infusion if there are particles floating in the solution or if the pack is damaged in any way.
Stop receiving your Sodium Chloride 0.18 & Glucose 4 Infusion Your doctor will decide when to stop giving you this infusion. If you have any further questions on the use of this medicine, ask your doctor or nurse.
Sodium Chloride 0.18 & Glucose 4 Infusion will usually be given to you through a plastic tube attached to a needle in a vein. Usually a vein in your arm is used to give you the infusion. However, your doctor may use another method to give you the medicine.
4. Possible side effects
Before and during the infusion, your doctor will monitor:
Like all medicines, this medicine can cause side effects, although not everybody gets them The side effects can be related to Sodium Chloride 0.18 & Glucose 4 Infusion itself. This includes:
If you receive more Sodium Chloride 0.18 & Glucose 4 Infusion than you should If you are given too much Sodium Chloride 0.18 & Glucose 4 Infusion (over-infusion) or if it is given too fast, this may lead to the following symptoms:
The side effects can be related to the administration technique. This includes:
high levels of sugar in the blood (hyperglycemia) Symptoms include:
If a medicine has been added to the solution for infusion, the added medicine may also cause side TH-30-02-199
4
The bag sizes are:
effects. These side effects will depend on the medicine that has been added. You should read the Package Leaflet of the added medicine for a list of possible symptoms.
The bags are supplied in cartons. Each carton contains one of the following quantities:
Reporting of side effects If you get any side effects, talk to your doctor or pharmacist or nurse. This includes any possible
not listed in this leaflet. You can also report side effects directly via the national reporting system listed below. By reporting side effects you can help provide more information on the safety of this medicine.
Marketing Authorisation Holder and Manufacturer Marketing Authorisation Holder:
United Kingdom: Via the Yellow Card Scheme at: www.mhra.gov.uk/yellowcard
Send all enquiries to this address United Kingdom: Baxter Healthcare Ltd. Caxton Way Thetford, Norfolk, IP24 3SE United Kingdom
Sodium Chloride 0.18 & Glucose 4 Infusion Keep this medicine out of the sight and reach of children. Sodium Chloride 0.18 & Glucose 4 Infusion does not require special storage conditions. Sodium Chloride 0.18 & Glucose 4 Infusion should NOT be given to you after the expiry date which is stated on the bag after EXP. The expiry date refers to the last day of that month. You should not be given Sodium Chloride 0.18 & Glucose 4 Infusion, if there are particles floating in the solution or if the unit is damaged in any way.
Manufacturers: Baxter Healthcare Limited Caxton Way Thetford Norfolk IP24 3SE United Kingdom Baxter SA Boulevard Rene Branquart, 80 B7860 Lessines Belgium
Bieffe Medital SA Ctra de Biescas-Senegüé 22666 Sabiñánigo (Huesca) Spain
What Sodium Chloride 0.18 & Glucose 4 Infusion contains The active substances are:
The leaflet was last revised in January 2024
For information about Sodium Chloride 0.18 & Glucose 4 Infusion or to request this leaflet in formats such as audio or large print please contact the Marketing Authorisation Holder: Tel: +44 (0)1635 206345.
The only other ingredient is water for injections. What Sodium Chloride 0.18 & Glucose 4 Infusion looks like and contents of the pack Sodium Chloride 0.18 & Glucose 4 Infusion is a clear solution, free from visible particles. It is supplied in polyolefin/polyamide plastic bags (Viaflo). Each bag is wrapped in a sealed, protective, outer plastic overpouch.
TH-30-02-199
5
Baxter and Viaflo are trademarks of Baxter International lnc.
TH-30-02-199
6
Sodium Chloride 0.18% w/v and Glucose 4% w/v Solution for Infusion BP The following information is intended for healthcare professionals only:
controlled and validated aseptic conditions. Discard after single use. Discard any unused portion. Do not reconnect partially used bags.
Handling and Preparation Use only if the solution is clear, without visible particles and if the container is undamaged. Administer immediately following the insertion of infusion set. Do not remove unit from overwrap until ready for use. The inner bag maintains the sterility of the product. Do not use plastic containers in series connections. Such use could result in air embolism due to residual air being drawn from the primary container before the administration of the fluid from the secondary container is completed. Pressurizing intravenous solutions contained in flexible plastic containers to increase flow rates can result in air embolism if the residual air in the container is not fully evacuated prior to administration. Use of a vented intravenous administration set with the vent in the open position could result in air embolism. Vented intravenous administration sets with the vent in the open position should not be used with flexible plastic containers. The solution should be administered with sterile equipment using an aseptic technique. The equipment should be primed with the solution in order to prevent air entering the system. Additives may be introduced before infusion or during infusion through the re-sealable medication port. When additive is used, verify tonicity prior to parenteral administration. From a physico-chemical viewpoint, solution containing additives should be used immediately unless chemical and physical in-use stability has been established. From a microbiological point of view, solutions containing additives should be used immediately. If not used immediately, in-use storage times and conditions prior to use are the responsibility of the user and should normally not be longer than 24 hours at 2 to 8°C, unless addition has taken place in
1. Opening a. Remove the Viaflo container from the overpouch just before use. b. Check for minute leaks by squeezing inner bag firmly. If leaks are found, discard solution, as sterility may be impaired. c. Check the solution for limpidity and absence of foreign matters. If solution is not clear or contains foreign matters, discard the solution.
2. Preparation for administration Use sterile material for preparation and administration. a. Suspend container from eyelet support. b. Remove plastic protector from outlet port at bottom of container:
3. Techniques for injection of additive medicinal products Warning: Additives may be incompatible (see Paragraph 5 "Incompatibilities of additive medicinal products" below). To add medicinal products before administration a. Disinfect medication port. b. Using syringe with 19 gauge (1.10 mm) to 22 gauge (0.70 mm) needle, puncture re-sealable medication port and inject. TH-30-02-199
7
incompatibility of an additive medicinal product with the Sodium Chloride 0.18 & Glucose 4 Infusion by checking for eventual colour change and/or eventual appearance of precipitate, insoluble complexes or crystals. The Instructions for Use of the medication to be added must be consulted. Before adding a drug, verify it is soluble and stable in water at the pH of Sodium Chloride 0.18 & Glucose 4 Infusion (pH 3.5 – 6.5). When a compatible medicinal product is added to the Sodium Chloride 0.18 & Glucose 4 Infusion, the solution must be administered immediately, unless chemical and physical in-use stability has been established. As guidance the following medicinal products are incompatible with the Sodium Chloride 0.18 & Glucose 4 Infusion (non-exhaustive listing):
c. Mix solution and medicinal product thoroughly. For high-density medicinal products such as potassium chloride, tap the ports gently while ports are upright and mix. Caution: for storage of bags containing additives, refer to In-use shelf-life instructions in section 4. To add medicinal products during administration a. Close clamp on the set. b. Disinfect medication port c. Using syringe with 19 gauge (1.10 mm) to 22 gauge (0.70 mm) needle, puncture re-sealable medication port and inject. d. Remove container from IV pole and/or turn to an upright position. e. Evacuate both ports by tapping gently while the container is in an upright position. f. Mix solution and medicinal product thoroughly. g. Return container to in use position, re-open the clamp and continue administration.
4. In-use shelf-life: Additives The chemical and physical stability of any additive at the pH of Sodium Chloride 0.18 & Glucose 4 Infusion in the Viaflo container should be established prior to use. From a physico-chemical viewpoint, solution containing additives should be used immediately unless chemical and physical in-use stability has been established. From a microbiological point of view, the diluted product must be used immediately. If not used immediately, in-use storage times and conditions prior to use are the responsibility of the user and would normally not be longer than 24 hours at 2 to 8°C unless dilution has taken place in controlled and validated aseptic conditions.
Because of the presence of glucose, Sodium Chloride 0.18 & Glucose 4 Infusion should not be administered through the same infusion equipment as whole blood, as haemolysis and clumping can occur. Those additives known to be incompatible should not be used.
5. Incompatibilities of additive medicinal products As with all parenteral solutions, before adding medicinal products, compatibility of these additives with the solution in Viaflo container must be assessed. It is the responsibility of the physician to judge the Baxter and Viaflo are trademarks of Baxter International lnc.
TH-30-02-199
8
Sodium Chloride 0.18% and Glucose 4 % Solution for Infusion BP comes as infusion. Always follow the dose your doctor or pharmacist has given you, and read the leaflet that comes with the medicine.
The active substance in Sodium Chloride 0.18% and Glucose 4 % Solution for Infusion BP is glucose monohydrate, sodium chloride.
Medicines with the same active substance, strength and form include: 5% GLUCOSE INTRAVENOUS INFUSION SOLUTION, Potassium Chloride 0.15 % w/v and Glucose 10 % w/v Solution for Infusion BP, Potassium Chloride 0.15 % w/v and Glucose 5% w/v Solution for Infusion -BP. In total there are 26 equivalent products. They are interchangeable only if your prescriber or pharmacist says so.
This leaflet reproduces the patient information leaflet approved for Sodium Chloride 0.18% and Glucose 4 % Solution for Infusion BP, as published on the electronic medicines compendium (emc). The version printed inside your medicine’s packaging is the one that applies to you.
Whether a medicine is available over the counter or on prescription only depends on its licence. Check the leaflet, or ask your pharmacist — they can tell you straight away.
The text above reproduces the patient information leaflet approved for this medicine, restructured for easier reading.
Sodium Chloride 0.18 % and Glucose 4% solution is used in the following indications:
Dehydration treatment due to a moderated loss of sodium and chloride (vomiting, diarrhoea, renal disorders, overuse of diuretics) in cases where a source of energy is required (particularly starvation).
Paediatric Population
This product should only be used in paediatric specialist settings (such as renal, hepatic and cardiac units, high dependency units and intensive care units) for intravenous fluid therapy requiring the use of 0.18% sodium chloride and 4% glucose to maintain fluid and electrolyte balance.
The choice of the specific sodium chloride and glucose concentration, dosage, volume, rate and duration of administration depends on the age, weight, clinical condition of the patient and concomitant therapy. It should be determined by a physician. For patients with electrolyte and glucose abnormalities and for paediatric patients, consult a physician experienced in intravenous fluid therapy.
Fluid balance, serum glucose, serum sodium and other electrolytes should be monitored before and during administration, especially in patients with increased non-osmotic vasopressin release (syndrome of inappropriate antidiuretic hormone secretion, SIADH) and in patients co-medicated with vasopressin agonist drugs due to the risk of hyponatraemia. Monitoring of serum sodium is particularly important for physiologically hypotonic fluids. Sodium Chloride 0.18 % w/v and Glucose 4% w/v solution may become extremely hypotonic after administration due to glucose metabolisation in the body (see sections 4.4, 4.5 and 4.8).
Rapid correction of hyponatraemia and hypernatraemia is potentially dangerous (risk of serious neurologic complications).
Electrolyte supplementation may be indicated according to the clinical needs of the patient.
Adults, older patients and adolescents (age 12 years and over):
The Recommended dosage is 500 ml to 3 L/24h
Administration rate
The infusion rate is usually 40 ml/kg/24h and should not exceed the patient's glucose oxidation capacities in order to avoid hyperglycaemia. Therefore the maximum acute administration rate is 5 mg/kg/min.
Paediatric Population
Use of 0.18% sodium chloride and 4% glucose should be restricted to specialist paediatric settings such as renal, hepatic and cardiac units, high dependency units and intensive care units.
The dosage varies with weight:
0-10 kg body weight:
10-20 kg body weight:
> 20 kg body weight:
100 ml/kg/24h
1000 ml + (50 ml/kg over 10 kg)/24h
1500 ml + (20 ml/kg over 20 kg)/24h.
The administration rate varies with weight:
0-10 kg body weight:
10-20 kg body weight:
> 20 kg body weight:
6-8 ml/kg/h
4-6 ml/kg/h
2-4 ml/kg/h
The infusion rate should not exceed the patient's glucose oxidation capacities in order to avoid hyperglycaemia. Therefore the maximum acute administration rate is 10-18 mg/kg/min, depending on the total body mass.
For all patients, a gradual increase of flow rate should be considered when starting administration of glucose containing products.
Method of administration
The administration is performed by intravenous infusion.
Sodium Chloride 0.18 % w/v and Glucose 4 % w/v solution is hypotonic and hyperosmolar, due to the glucose content.
Precautions to be taken before manipulating or administering the product
Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration. Do not administer unless the solution is clear and the seal is intact. Administer immediately following the insertion of infusion set.
Do not remove unit from overwrap until ready for use.
The inner bag maintains the sterility of the product.
The solution should be administered with sterile equipment using an aseptic technique.
The equipment should be primed with the solution in order to prevent air entering the system.
Do not use plastic containers in series connections. Such use could result in air embolism due to residual air being drawn from the primary container before the administration of the fluid from the secondary container is completed.
Pressurizing intravenous solutions contained in flexible plastic containers to increase flow rates can result in air embolism if the residual air in the container is not fully evacuated prior to administration.
Use of a vented intravenous administration set with the vent in the open position could result in air embolism. Vented intravenous administration sets with the vent in the open position should not be used with flexible plastic containers.
Additives may be introduced before or during infusion through the resealable medication port. When additive is used, verify tonicity prior to parenteral administration. Hyperosmolar solutions may cause venous irritation and phlebitis. Thus, any hyperosmolar solution is recommended to be administered through a large central vein, for rapid dilution of the hyperosmotic solution.
For further information on the product with additives, please see sections 6.2, 6.3 and 6.6.
The solution is contraindicated in patients presenting with:
• Known hypersensitivity to the product
• Extracellular hyperhydration or hypervolaemia
• Fluid and sodium retention
• Severe renal insufficiency (with oliguria/anuria)
• Uncompensated cardiac failure
• Hyponatraemia or hypochloraemia
• General oedema and ascitic cirrhosis
• Clinically significant hyperglycaemia.
The solution is also contraindicated in case of uncompensated diabetes, other known glucose intolerances (such as metabolic stress situations), hyperosmolar coma or hyperlactataemia.
Paediatric Population
This product should not be used in children except in paediatric specialist settings (such as renal, hepatic and cardiac units high dependency units and intensive care units) under expert medical supervision.
Glucose intravenous infusions are usually isotonic solutions. In the body, however, glucose containing fluids can become extremely physiologically hypotonic due to rapid glucose metabolization (see section 4.2).
Depending on the tonicity of the solution, the volume and rate of infusion and depending on a patient's underlying clinical condition and capability to metabolize glucose, intravenous administration of glucose can cause electrolyte disturbances most importantly hypo- or hyperosmotic hyponatraemia.
Hyponatraemia
The infusion of solutions with sodium concentrations <0.9% may result in hyponatraemia. Close clinical monitoring may be warranted.
Patients with non-osmotic vasopressin release (e.g. in acute illness, pain, post-operative stress, infections, burns, and CNS diseases), patients with heart-, liver- and kidney diseases and patients exposed to vasopressin agonists (see section 4.5) are at particular risk of acute hyponatraemia upon infusion of hypotonic fluids.
Acute hyponatraemia can lead to acute hyponatraemic encephalopathy (brain oedema) characterized by headache, nausea, seizures, lethargy and vomiting. Patients with brain oedema are at particular risk of severe, irreversible and life-threatening brain injury.
Children, women in the fertile age and patients with reduced cerebral compliance (e.g. meningitis, intracranial bleeding, and cerebral contusion) are at particular risk of the severe and life-threatening brain swelling caused by acute hyponatraemia
Sodium retention, fluid overload and oedema
Sodium Chloride 0.18 % w/v and Glucose 4 % w/v solution should be used with particular caution, in:
• Patients with conditions that may cause sodium retention, fluid overload and oedema (central and peripheral), such as
o Primary hyperaldosteronism,
o Secondary hyperaldosteronism associated with, for example,
- hypertension,
- congestive heart failure,
- liver disease (including cirrhosis),
- renal disease (including renal artery stenosis, nephrosclerosis)
o Pre-eclampsia.
• Patients taking medications that may increase the risk of sodium and fluid retention, such as corticosteroids
Hypokalaemia
The infusion of Sodium Chloride 0.18 % w/v and Glucose 4 % w/v solution may result in hypokalaemia. This medicine should be used with particular caution in patients with or at risk for hypokalemia. Close clinical monitoring may be warranted in, for example:
• persons with metabolic alkalosis
• persons with thyrotoxic periodic paralysis, administration of intravenous glucose has been associated in aggravating hypokalaemia
• persons with increased gastrointestinal losses (e.g., diarrhea, vomiting)
• prolonged low potassium diet
• persons with primary hyperaldosteronism
• patients treated with medications that increase the risk of hypokalaemia (e.g. diuretics, beta-2 agonist, or insulin)
Hypo- and hyperosmolality, serum electrolytes and water imbalance
Depending on the volume and rate of infusion and depending on a patient's underlying clinical condition and capability to metabolize glucose, intravenous administration of Sodium Chloride 0.18 % w/v and Glucose 4 % w/v solution can cause:
• Hypo-osmolality
• Hyperosmolality, osmotic diuresis and dehydration
• Electrolyte disturbances such as
o hyponatraemia (see above),
o hypokalaemia (see above),
o hypophosphataemia,
o hypomagnesaemia,
• Overhydration/hypervolaemia and, for example, congested states, including central (e.g., pulmonary congestion) and peripheral oedema.
Clinical evaluation and periodic laboratory determinations may be necessary to monitor changes in fluid balance, electrolyte concentrations and acid-base balance during prolonged parenteral therapy or whenever the condition of the patient or the rate of administration warrants such evaluation.
Hyperglycaemia
Rapid administration of glucose solutions may produce substantial hyperglycaemia and a hyperosmolar syndrome. In order to avoid hyperglycaemia the infusion rate should not exceed the patient's ability to utilize glucose.
To reduce the risk of hyperglycaemia-associated complications, the infusion rate must be adjusted and/or insulin administered if blood glucose levels exceed levels considered acceptable for the individual patient.
Intravenous glucose should be administered with caution in patients with, for example:
• impaired glucose tolerance (such as in diabetes mellitus, renal impairment, or in the presence of sepsis, trauma or shock),
• severe malnutrition (risk of precipitating a refeeding syndrome, see below),
• thiamine deficiency, e.g., in patients with chronic alcoholism (risk of severe lactic
• acidosis due to impaired oxidative metabolism of pyruvate),
• water and electrolyte disturbances that could be aggravated by increased glucose and/or free water load
Other groups of patients in whom Sodium Chloride 0.18 % w/v and Glucose 4 % w/v solution should be used with caution include:
• patients with ischemic stroke. hyperglycaemia has been implicated in increasing cerebral ischemic brain damage and impairing recovery after acute ischemic strokes.
• patients with severe traumatic brain injury (in particular during the first 24 hours following the trauma). Early hyperglycaemia has been associated with poor outcomes in patients with severe traumatic brain injury.
• Newborns (see Paediatric glycaemia-related issues).
Prolonged intravenous administration of glucose and associated hyperglycaemia may result in decreased rates of glucose-stimulated insulin secretion.
Hypersensitivity Reactions
• Hypersensitivity/infusion reactions, including anaphylaxis, have been reported (see section 4.8).
• Stop the infusion immediately if signs or symptoms of hypersensitivity/infusion reactions develop. Appropriate therapeutic countermeasures must be instituted as clinically indicated.
• Solutions containing glucose should be used with caution in patients with known allergy to corn or corn products
Refeeding syndrome
Refeeding severely undernourished patients may result in the refeeding syndrome that is characterized by the shift of potassium, phosphorus and magnesium intracellularly as the patient becomes anabolic. Thiamine deficiency and fluid retention may also develop. Careful monitoring and slowly increasing nutrient intake while avoiding overfeeding can prevent these complications.
Severe renal impairment
Sodium Chloride 0.18 % w/v and Glucose 4 % w/v solution should be administered with particular caution to patients at risk of (severe) renal impairment. In such patients, administration may result in sodium retention and/or fluid overload.
Paediatric use
The infusion rate and volume depends on the age, weight, clinical and metabolic conditions of the patient, concomitant therapy, and should be determined by a physician experienced in paediatric intravenous fluid therapy.
Paediatric Population
Intravenous fluid therapy should be closely monitored in the paediatric populations as they may have impaired ability to regulate fluids and electrolytes. Adequate urine flow must be ensured and careful monitoring of fluid balance, plasma and urinary electrolyte concentrations are essential.
Paediatric glycaemia-related issues
Newborns, especially those born premature and with low birth weight, are at increased risk of developing hypo- or hyperglycaemia. Close monitoring during treatment with intravenous glucose solutions is needed to ensure adequate glycaemic control, in order to avoid potential long term adverse effects.
Hypoglycaemia in the newborn can cause, e.g.,
• prolonged seizures,
• coma and
• cerebral injury.
Hyperglycaemia has been associated with
• cerebral injury, including intraventricular haemorrhage,
• late onset bacterial and fungal infection,
• retinopathy of prematurity,
• necrotizing enterocolitis,
• increased oxygen requirements,
• prolonged length of hospital stay and
• death.
Paediatric hyponatraemia-related issues
• Children (including neonates and older children) are at increased risk of developing hyponatraemia as well as for developing hyponatraemic encephalopathy.
• The infusion of hypotonic fluids together with the non-osmotic secretion of ADH may result in hyponatraemia.
• Hyponatraemia can lead to headache, nausea, seizures, lethargy, coma, cerebral edema and death; therefore, acute symptomatic hyponatraemic encephalopathy is considered a medical emergency.
• Plasma electrolyte concentrations should be closely monitored in the paediatric population.
• Rapid correction of hyponatraemia is potentially dangerous (risk of serious neurologic complications). Dosage, rate, and duration of administration should be determined by a physician experienced in paediatric intravenous fluid therapy.
Blood
Sodium Chloride 0.18 % w/v and Glucose 4 % w/v solution should not be administered simultaneously with blood through the same administration set because of the possibility of pseudoagglutination or haemolysis.
Geriatric use
When selecting the type of infusion and the volume/rate of infusion for a geriatric patient, consider that geriatric patients are generally more likely to have cardiac, renal, hepatic, and other diseases or concomitant drug therapy.
No studies have been conducted by Baxter.
Both the glycaemic and effects on water and electrolyte balance should be taken into account when administering Sodium Chloride 0.18% w/v and Glucose 4% w/v solution to patients treated with other substances that affect glycaemic control or fluid and/or electrolyte balance.
Drugs leading to an increased vasopressin effect
The below listed drugs increase the vasopressin effect, leading to reduced renal electrolyte free water excretion and increase the risk of hospital acquired hyponatraemia following inappropriately balanced treatment with i.v. fluids (see sections 4.2, 4.4 and 4.8).
• Drugs stimulating vasopressin release, e.g.: Chlorpropamide, clofibrate, carbamazepine, vincristine, selective serotonin reuptake inhibitors, 3.4-methylenedioxy-N-methamphetamine, ifosfamide, antipsychotics, narcotics
• Drugs potentiating vasopressin action, e.g.: Chlorpropamide, NSAIDs, cyclophosphamide
• Vasopressin analogues, e.g.: Desmopressin, oxytocin, terlipressin
Other medicinal products increasing the risk of hyponatraemia also include diuretics in general and antiepileptics such as oxcarbazepine.
Caution is advised in patients treated with
• lithium. Renal sodium and lithium clearance may be increased during administration and can result in decreased lithium levels.
• corticosteroids, which are associated with the retention of sodium and water (with oedema and hypertension).
• diuretics, beta-2 agonist, or insulin, whom increase the risk of hypokalemia
• certain antiepileptic and psychotropic medications that increase the risk of hyponatraemia.
Pregnancy
Intrapartum maternal intravenous glucose infusion may result in foetal hyperglycaemia and metabolic acidosis as well as rebound neonatal hypoglycaemia due to foetal insulin production.
Sodium Chloride 0.18 % w/v and Glucose 4% w/v solution should be administrated with special caution for pregnant women during labour particularly if administered in combination with oxytocin due to the risk of hyponatraemia (see section 4.4, 4.5 and 4.8).
Fertility
There is no information on the effects of Sodium Chloride 0.18% w/v and Glucose 4% w/v solution on fertility
Lactation
Sodium Chloride 0.18% w/v and Glucose 4% w/v solution can be used during breast-feeding. The potential risks and benefits for each specific patient should be carefully considered before administration.
There is no information on the effects of Sodium Chloride 0.18 % w/v and Glucose 4% w/v solution on the ability to operate an automobile or other heavy machinery
The following adverse reactions have been reported in post-marketing experience, listed by MedDRA System Organ Class (SOC), then where feasible, by Preferred Term in order of severity.
Frequencies cannot be estimated from the available data as all listed adverse reactions are based on spontaneous reporting
System Organ Class
Adverse reactions (Preferred terms)
Frequency
Metabolism and nutrition disorders
Hypervolaemia
Not known
Electrolyte imbalance
Not known
hospital acquired hyponatraemia*
Not known
Hyponatraemia*
Not known
Nervous system disorders
hyponatraemic encephalopathy**
Not known
Cardiac disorders
Cardiac failure
Not known
Renal and urinary disorders
Polyuria
Not known
Immune system disorders
Hypersensitivity
Not known
Anaphylactic reaction
Not known
*Potential manifestation in patients with allergy to corn, see section 4.4
** Hospital acquired hyponatraemia may cause irreversible brain injury and death due to development of acute hyponatraemic encephalopathy (see sections 4.2 and 4.4).
Adverse reactions may be associated to the medicinal product(s) added to the solution; the nature of the additive will determine the likelihood of any other adverse reactions.
System Organ Class
Adverse reactions (Preferred Terms)
Frequency
Metabolism and nutrition disorders
Hypervolaemia
Not known
Vascular disorders
Vein injury
Not known
Thrombophlebitis superficial
Not known
General disorders and administration site conditions
Chills
Not known
Pyrexia
Not known
Application site infection
Not known
Application site pain
Not known
Application site reaction
Not known
Injection site phlebitis
Not known
Injection site extravasation
Not known
Reporting of suspected adverse reactions
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme.
Website: www.mhra.gov.uk/yellowcard
Excess administration of Sodium Chloride 0.18 % w/v and Glucose 4 % w/v solution can cause:
• Hyperglycaemia, adverse effects on water and electrolyte balance, and corresponding complications. For example, severe hyperglycaemia and severe dilutional hyponatraemia, and their complications, can be fatal.
• Hyponatraemia (which can lead to CNS manifestations, including seizures, coma, cerebral oedema and death).
• Fluid overload (which can lead to central and/or peripheral oedema).
• See also sections 4.4 and 4.8
When assessing an overdose, any additives in the solution must also be considered.
Clinically significant overdose of Sodium Chloride 0.18% w/v and Glucose 4% w/v solution may therefore, constitute a medical emergency.
Interventions include discontinuation of administration, dose reduction, administration of insulin and other measures as indicated for the specific clinical constellation.
Ask anything about Sodium Chloride 0.18% and Glucose 4 % Solution for Infusion BP. The assistant answers only from this leaflet — if the leaflet does not cover it, it will say so. It does not give medical advice.
Answers come from the patient leaflet published on the electronic medicines compendium (emc). They are not medical advice. Ask a pharmacist or your GP if you are unsure. For urgent help call NHS 111, or 999 in an emergency.
We use essential cookies to make the site work. We would also like to set optional cookies to understand how the site is used, so we can improve it. We will not set optional cookies unless you accept. See our cookie policy and privacy policy.